Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Perennial Allergic Rhinitis Pipeline Review, H2 2016 - 7 Companies & 10 Molecules - Research and Markets

Research and Markets
Posted on: 28 Sep 16

Research and Markets has announced the addition of the "Perennial Allergic Rhinitis - Pipeline Review, H2 2016" report to their offering.

Perennial Allergic Rhinitis pipeline therapeutics constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities Institutes.

Furthermore, the publisher says; Perennial Allergic Rhinitis Perennial allergic rhinitis is an allergy that occurs all year round and is caused by things such as house dust mites and pets. Symptoms include itching in the nose, roof of the mouth, throat, eyes, sneezing, stuffy nose (congestion), runny nose, tearing eyes and dark circles under the eyes. Treatment includes antihistamines, decongestants and corticosteroids.

The report 'Perennial Allergic Rhinitis - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Perennial Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Perennial Allergic Rhinitis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III and Phase I stages are 2, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Perennial Allergic Rhinitis Overview
  3. Therapeutics Development
  4. Pipeline Products for Perennial Allergic Rhinitis - Overview
  5. Pipeline Products for Perennial Allergic Rhinitis - Comparative Analysis
  6. Perennial Allergic Rhinitis - Therapeutics under Development by Companies
  7. Perennial Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes
  8. Perennial Allergic Rhinitis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Perennial Allergic Rhinitis - Products under Development by Companies
  13. Perennial Allergic Rhinitis - Products under Investigation by Universities/Institutes
  14. Perennial Allergic Rhinitis - Companies Involved in Therapeutics Development
  • Faes Farma, S.A.
  • Glenmark Pharmaceuticals Ltd.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Shionogi & Co., Ltd.
  • VentiRx Pharmaceuticals, Inc.

For more information about this report visit

View source version on

Business Wire

Last updated on: 28/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.